Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609266 | 0.88 | ALOX5 (0.57) | ALOX5L3MBTL1PTGS1PTGS2FFAR1 | |
| SCHEMBL6609269 | 0.88 | ALOX5 (0.57) | ALOX5L3MBTL1PTGS1PTGS2FFAR1 | |
| SCHEMBL31109316 | 0.88 | TRPM8 (0.42) | ALOX5L3MBTL1LMNAALDH1A1 | |
| SCHEMBL31109220 | 0.87 | F2 (0.43) | ALOX5L3MBTL1LMNAALDH1A1 | |
| SCHEMBL31109250 | 0.85 | LPAR1 (0.47) | ALOX5L3MBTL1LMNAPTGS2ALDH1A1 | |
| SCHEMBL30671411 | 0.82 | PPARG (0.41) | L3MBTL1LMNAALDH1A1 | |
| SCHEMBL30671403 | 0.82 | F10 (0.42) | ALOX5L3MBTL1LMNAALDH1A1FFAR1 | |
| SCHEMBL31109286 | 0.81 | PTGES (0.46) | ALOX5LMNAPTGS1ALDH1A1FFAR1 | |
| SCHEMBL13143762 | 0.81 | F10 (0.44) | ALOX5L3MBTL1LMNAALDH1A1 | |
| SCHEMBL20857397 | 0.81 | F10 (0.44) | L3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ALOX5 2901/4885L3MBTL1 2252/4885LMNA 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.